The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
And so, they initially thought that it might be a good drug as an antifungal, but it's a lousy antifungal. And so, they were trying to figure out what else could it do, and they found out that it's a really potent immunosuppressant. And in fact, the research into the immunosuppressor role ended up really accelerating understanding of how the mTOR pathway works in the first place.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
It was found in... - So rapamycin, or sirolimus, the other name for it, was found in the soil of the island of Rapa Nui, and there was a researcher at Wyeth Pharmaceuticals who was going all around the Pacific Ocean to a bunch of different islands and picking up soil samples.
Rapomyone was first discovered in the 1960s by scientists gathering a soil sample in a cave on Easter Island. In that soil sample, they found a bacterium that had powerful antifungal properties. They named that compound rapamy.
Island repays humanity with rapamycin, a lifesaving and possible lifespan extending drug.
And obviously the reason we went to Easter Island was as sort of a pilgrimage based on the discovery of the bacteria that ultimately led to rapamycin, a bacteria by the name of streptomyces hydrocophagus.
now flash forward several decades a molecules discovered on Easter Island made by soil bacterium it's one of your favorite molecules rapamycin now the aging affects a rapamycin were not figured out until about 2003
and I actually think and Matt may may correct me I think some of the earlier assays were actually immunological assays even before some of the antifungal assays um and and that eventually led many decades after to pursuing it as an immunosuppressant
in that soil sample actually in Canada people eventually isolated bacteria from it bacteria called streptomyces hopus and from that bacteria Romy was eventually isolated and in deference to Rapa nui was named Romy
in that soil sample actually in Canada people eventually isolated bacteria from it like Tara Colts streptomyces hydropicus and from that bacteria rapamycin was eventually isolated and in deference to Rapa Nui was named rapamycin
at a high level right Ramy is a substance that was discovered from a bacteria discovered on Easter Island in the god probably the mid-60s 6667 um bacteria if I'm not mistaken was streptomyces hydroscopic at the time a very novel organism that had never been discovered anywhere else and it secreted this chemical that was named Ramy to honor the uh Island where it was discovered rapanui
at a high level Ramy is a substance that was discovered from a bacteria discovered on Easter Island in the god probably the mid-60s 6667 um bacteria if I'm not mistaken was streptomyces hydroscopic at the time a very novel organism that had never been discovered anywhere else and it secreted this chemical that was named ramyon to honor the uh Island where it was discovered rapanui and um this molecule was clearly found to be a very potent antifungal
So, this this rapamy is discovered on Easter Island and you've probably gone through the whole story of this.
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.